> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 14 Observations on Houston Rx FDA-483
- URL: https://www.fdaweb.com/14-observations-on-houston-rx-fda-483/
- Published: 2026-10-01T20:43:13.000Z
- Updated: 2026-10-01T20:43:13.000Z
- Author: David McFarland
- Tags: Drugs

FDA has released the Form FDA-483 issued following an 8/20-8/28 inspection at Houston Rx, a Houston, TX, producer of sterile drugs. The 14 inspection observations were:

- personnel performed aseptic manipulations with exposed hair or skin;
- a pattern of frequent or acute pressure reversals was observed from areas of less clean air to areas of higher air cleanliness;
- inadequate redacted testing on a redacted product used to sterilize drugs;
- personnel were observed manually contacting the inner surface of a sterile container or closure and manually touching a sterile product contact surface;
- microbial contamination was present in the ISO 5 area;
- the facility is designed and/or operated in a way that permits poor flow of personnel or materials;
- sterile drugs were exposed to lower than ISO 5 quality air;
- failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most challenging, and stressful conditions;
- use of ingredients not intended for pharmaceutical use in sterile drug production;
- contamination was observed in areas adjacent to production areas;
- use of cleaning and disinfecting agents that may leave residues or not adequately rinsing such agents from containers, closures, or equipment that comes into direct contact with drug products;
- sterile products were exposed to non-sterile or non-depyrogenated supplies;
- failure to use biological indicators to verify the adequacy of the sterilization cycle; and
- failure to store active pharmaceutical ingredients per the labeled storage conditions.